WANTAI BIOLOGICAL(SH:603392) Mei Ri Jing Ji Xin Wen·2026-02-12 12:49Core Viewpoint - The chairman of Wantai Biological Pharmacy (万泰生物), Qiu Zixin, plans to reduce his shareholding through a centralized bidding method, with all proceeds from the sale intended for donation to Xiamen University Education Development Foundation and Xiamen No. 1 Middle School, raising investor interest and media attention [1][4]. Company Overview - Wantai Biological, established in 1991, focuses on the research, production, and sales of diagnostic reagents, vaccines, and medical devices, with its main business divided into in vitro diagnostics and vaccines [1]. - The actual controller of Wantai Biological is Zhong Shanshan, who holds 73.49% of the company's shares [1]. Shareholding Reduction Plan - Qiu Zixin plans to reduce his holdings by up to 5 million shares, representing no more than 0.3954% of the total share capital, between March 12, 2026, and June 11, 2026 [5]. - As of now, Qiu Zixin holds 3.5469% of Wantai Biological's shares [1]. HPV Vaccine Development - Wantai Biological has a strong position in the HPV vaccine sector, having launched the domestically developed bivalent HPV vaccine (Xinkening) in 2019, which was the first of its kind in China, and is expected to launch the nine-valent HPV vaccine (Xinkening 9) in 2025 [1]. Financial Performance and Market Reaction - In 2025, Wantai Biological's stock price fell by 36.22%, and the company is projected to report its first loss since its listing, with an expected net loss of between 330 million to 410 million yuan [6]. - Following the announcement of the share reduction plan, the company's stock price experienced a slight decline over three consecutive days, nearing its October 2023 low, with a closing price of 40.47 yuan and a market capitalization of approximately 51.17 billion yuan [6]. Investor Concerns - Investors have expressed concerns regarding the potential impact of the share reduction on market liquidity, the choice of centralized bidding over block trading, and the complexity of the donation process [7].